Alnylam Pharmaceuticals, Inc.

NASDAQ: ALNY
$136.14
-$1.29 (-0.9%)
Closing price August 14, 2020
Thursday's top analyst upgrades, downgrades and initiations included Advanced Micro Devices, Applied Materials, Carnival, Dell, Karuna Therapeutics, Lowe's, Noble Energy, PayPal, Square, Target and...
Wednesday's top analyst upgrades, downgrades and initiations include Amarin, Baker Hughes, Canopy Growth, Home Depot, Intelsat, Johnson & Johnson, Replimune, Schlumberger and Transocean.
Alnylam Pharma and Regeneron Pharma shares dipped on Monday despite announcing a collaboration to discover, develop and commercialize new RNA interference therapeutics for a broad range of diseases.
The top analyst upgrades, downgrades and other research calls from Monday included Akamai, Dollar Tree, Hasbro, Intel, Mylan, Netflix and Papa John's.
The top analyst upgrades, downgrades and other research calls from Tuesday include Broadcom, CBS, Etsy, Illumina, PulteGroup, SeaWorld, Wynn Resorts and Zillow.
Here is a 24/7 Wall St. calendar with a few of the biggest biotech and pharmaceutical companies expecting clinical trial and FDA updates in April.
The top analyst upgrades, downgrades and other research calls from Wednesday include Accenture, American Expresss, Cognizant Technology Solutions, FireEye, Mastercard, PayPal, Verizon and Visa.
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates for the rest of March.
Jefferies has put together a list of 10 biotech companies that could have developments coming up in the next two weeks to start the year.
With 2017 nearing an end, it is important to consider just what has happened. 24/7 Wall St. has screened 50 stocks that have risen 100% or more (some far more) in 2017.
The top analyst upgrades, downgrades and other research calls from Monday include AMD, Chevron, GM, Intel, Merck, Nokia and Under Armour.
Source: courtesy of Jon OggStocks were indicated to open higher on Monday after hitting all-time highs the prior week. The one trend that has been proven time after time in this eight-year bull...
The top analyst upgrades, downgrades and other research calls from Wednesday include Axovant, Carnival, Micron Technology, Nike, SunPower, Vivint Solar and Walgreens.
The top analyst upgrades, downgrades and other research calls from Thursday include AMD, Biogen, Capital One, Intuit, Jinko Solar, Micron Technology, Albermarle and Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals saw its shares make a handy gain on Wednesday after the firm gave an update on its late-stage trial in patients with hereditary ATTR amyloidosis with polyneuropathy.